Q1 2025 Sangamo Therapeutics Inc Earnings Call Transcript
Key Points
- Sangamo Therapeutics Inc (SGMO) signed a third capsid license agreement with Eli Lilly, potentially earning up to $1.4 billion in milestone payments.
- The company is advancing its neurology pipeline, including preparations for a Phase I/II study of ST-503 for chronic neuropathic pain.
- Sangamo achieved significant clinical and regulatory milestones for its Fabry disease program, with a clear pathway to a BLA submission.
- The company has reduced non-GAAP operating expenses by 50% year-on-year, focusing on core priorities.
- Sangamo is actively engaging in promising business development discussions across its technology platforms, indicating ongoing interest in its innovations.
- Sangamo Therapeutics Inc (SGMO) requires additional funding to continue operations and achieve its milestones.
- The company announced an equity offering to extend its cash runway, indicating immediate financial needs.
- There is uncertainty regarding the statistical analysis plan for the Fabry disease program, with limited details shared.
- Sangamo's financial strategy relies heavily on securing a commercial partnership for its Fabry program.
- The company faces challenges in maintaining collaborations and strategic partnerships, crucial for its financial stability.
Good afternoon, and welcome to the Sangamo Therapeutics' first-quarter 2025 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations and Corporate Communications. Please go ahead.
Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Prathyusha Duraibabu, Chief Financial Officer; and Nathalie Dubois-Stringfellow, Chief Development Officer. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section.
This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to Sangamo's cash runway and operating expense guidance, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
